Multiple myeloma is a complex disease and immune dysfunction has been known to play
an important role in the disease pathogenesis, progression, and drug resistance. Recent …

This study aims to evaluate the efficacy and safety of Daratumumab-based induction
therapy (DBI) in newly diagnosed multiple myeloma (MM). We identified four eligible RCTs …

Monoclonal paraproteinaemia is an increasingly common reason for referral to haematology
services. Paraproteinaemias may be associated with life-threatening haematologic …

Multiple myeloma (MM) patients with suboptimal response to induction therapy or early
relapse, classified as the functional high-risk (FHR) patients, have been shown to have poor …

… Cinnie Yentia Soekojo has no relevant conflicts of interest to declare. Wee Joo Chng has
received honoraria from Janssen, Bristol-Myers Squibb-Celgene, Sanofi, Takeda, Amgen, …

Immunoglobulin M monoclonal gammopathy of undetermined significance (MGUS) comprises
15-20% of all cases of MGUS. IgM MGUS is distinct from other forms of MGUS in that the …

Pomalidomide is a third generation immunomodulatory drug which in combination with
dexamethasone, has been shown to be active in relapsed/refractory multiple myeloma. However, …

Objectives This review discusses the role of immune dysfunction at the different stages of
multiple myeloma (MM). Methods Narrative review. Results MM is a complex disease and …

Introduction: Multiple myeloma (MM) is the most frequent primary malignancy of the spine.
We aimed to investigate the clinical presentation, surgical indications and outcomes, …

Background Body fatness is associated with risk of coronary heart disease and it has been
postulated that epicardial adipose tissue (EAT) may have a particularly detrimental effect …